Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update
Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises Initiation
Reports
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Received IND clearance and initiated first-in-human Phase 1 clinical trial for lead asset, ADI-001, an
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update
We expect to report top line data from our Phase 2 cystic fibrosis clinical trials
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing
22nd Century Team Reports Small business Highlights and Economic Success for the Fourth Quarter and … | Income
Hemp/Hashish Franchise Highlights and Recent Essential Gatherings Given that reporting 3rd quarter earnings, 22nd Century
22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2020
Key Business and Financial Highlights 22nd Century has a tremendous global commercial opportunity in the
Health: Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Nasdaq:AQST
News Highlights Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results
PCDH19 related epilepsy (PCDH19-RE) Phase 2 Violet Study Proof-of-Concept Trial (n=21) shows a median 61.5{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4}
ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020
ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020 Conference call
Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Sale of Manufacturing Operations to Catalent with net proceeds of ~$74 million Annual operating expenses
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01
VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update
BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or
Ampio Pharmaceuticals, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update
The MarketWatch News Department was not involved in the creation of this content. ENGLEWOOD, Colo.,
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb 23, 2021– Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
2020 Net Revenues of $83.1 Million Increased 19{f13b67734a7459ff15bce07f17c500e58f5449212eae0f7769c5b6fbcf4cc0c4} over 2019 Fourth Quarter Net Revenues of
Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch –
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
NEW HAVEN, Conn., March 1, 2021 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven” or the